Featured Research

from universities, journals, and other organizations

Reduced intensity regimen prior to marrow transplant better for older leukemia patients, study suggests

Date:
December 9, 2012
Source:
Ohio State University Medical Center
Summary:
A new study shows that preparing older acute myeloid leukemia patients for bone marrow transplants with a reduced intensity conditioning regimen appears to be associated with higher rates of disease-free survival relative to the more typical treatments usually given to such patients.

A new study led by researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) shows that preparing older acute myeloid leukemia (AML) patients for bone marrow transplants with a reduced intensity conditioning regimen appears to be associated with higher rates of disease-free survival relative to the more typical treatments usually given to such patients. The study was presented at the 2012 American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

Typically, the prognosis for older AML patients is poor. Even in patients who achieve complete remission through chemotherapy, survival rates remain low due to high risk of relapse. While blood or bone marrow transplants can be a viable option for younger patients, conventional preparative regimens leading up to the procedure are often too toxic for patients over the age of 60.

"With a reduced intensity regimen leading up to a transplant, the disease free survival rate in older patients reached 39 percent," said Steven M. Devine, MD, Professor of Internal Medicine in the Division of Hematology at The Ohio State University Comprehensive Cancer Center, and director of the Blood and Marrow Transplant Program. "These outcomes are better than those achieved using more conventional treatments and warrant additional comparison research and studies focused on preventing relapse in this patient population."

Methodology & Results

The objective of the Phase II, prospective, multi-center trial was to determine the feasibility and effectiveness of a uniform reduced intensity conditioning regimen prior to a blood cell transplant in older AML patients in clinical remission. The primary endpoint of the study was two-year disease-free survival. Researchers hypothesized that disease-free survival at two years would exceed 20 percent. One hundred twenty three AML patients in first clinical remission following chemotherapy, ages 60-74, were transplanted at 21 centers across the country. Forty seven percent of patients had match related donors and 53 percent had unrelated donors. All but eight patients (who received fludarabine and busulfan alone) were conditioned with the same regimen containing fludarabine (30mg/m2/day x 5), busulfan (6.4mg/kg IV total dose) and antithymocyte globulin (7.5mg/kg total dose). One case of primary graft failure was reported. Rates of both acute and chronic graft vs host disease and treatment related mortality were relatively low. There were no unexpected toxicities associated with these transplants.. Relapse was the most common cause of death.


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University Medical Center. "Reduced intensity regimen prior to marrow transplant better for older leukemia patients, study suggests." ScienceDaily. ScienceDaily, 9 December 2012. <www.sciencedaily.com/releases/2012/12/121209165652.htm>.
Ohio State University Medical Center. (2012, December 9). Reduced intensity regimen prior to marrow transplant better for older leukemia patients, study suggests. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/12/121209165652.htm
Ohio State University Medical Center. "Reduced intensity regimen prior to marrow transplant better for older leukemia patients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/12/121209165652.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins